Governance at Theranos (A): A blindsided board Custom Case Solution & Analysis

Case Evidence Brief: Governance at Theranos (A)

1. Financial Metrics

• Valuation: Peak private market valuation reached 9 billion dollars.
• Capital Raised: Total equity funding exceeded 700 million dollars from private investors.
• Ownership Structure: Elizabeth Holmes held 50 percent of total shares but controlled 99 percent of voting power through Class B super-voting shares.
• Financial Reporting: The company did not produce audited financial statements for board review during the primary growth phase.

2. Operational Facts

• Core Product: The Edison device, a proprietary blood-testing machine designed to perform hundreds of tests on a single drop of blood.
• Board Composition: 12 members including former Secretaries of State, former Senators, and retired Generals. Only 2 members possessed medical or public health backgrounds.
• Regulatory Status: The company operated under Laboratory Developed Test (LDT) exemptions to avoid full FDA pre-market approval for the Edison.
• Internal Controls: Technical data remained siloed; departments were prohibited from communicating with one another regarding device performance.

3. Stakeholder Positions

• Elizabeth Holmes (CEO): Maintained absolute control over all strategic and operational decisions. Asserted that technical transparency would compromise trade secrets.
• George Shultz (Director): Former Secretary of State who championed Holmes and the company, even when presented with internal concerns from his grandson.
• Tyler Shultz (Whistleblower): Former employee who identified significant inaccuracies in the Edison testing results and reported them to regulators.
• Sunny Balwani (COO): Managed daily operations and enforced strict internal secrecy and employee surveillance.

4. Information Gaps

• Technical Validation: No independent, peer-reviewed data existed to confirm the Edison device accuracy.
• Revenue Composition: The case does not specify what percentage of revenue came from the Edison versus traditional third-party machines.
• Board Meeting Minutes: Records of board pushback or formal dissent regarding technical failures are absent.

Strategic Analysis

1. Core Strategic Question

• How can a board exercise fiduciary oversight when the founder holds absolute voting control and the core technology is shielded from technical scrutiny?

2. Structural Analysis

The governance failure at Theranos stems from a breakdown in Agency Theory. In a typical corporate structure, the board acts as the principal to monitor the agent (CEO). At Theranos, the dual-class share structure inverted this relationship. The board became an advisory body with no mechanism to remove the CEO or force transparency. The Board Composition Matrix reveals a fatal lack of technical expertise. Directors were selected for political capital and prestige rather than the ability to audit medical technology. This created a high-reputation, low-competence environment where the board could not distinguish between proprietary secrets and technical failure.

3. Strategic Options

4. Preliminary Recommendation

The board must immediately mandate an independent technical audit. Fiduciary duty to patient safety and legal compliance outweighs the risk of valuation loss. If the founder refuses, the board must resign en masse to signal a lack of confidence to investors and regulators. Maintaining the status quo is a tacit endorsement of potential fraud.

Implementation Roadmap

1. Critical Path

• Day 1 to 15: Form a Special Committee on Technical Validation consisting of the two directors with medical backgrounds. Hire an independent laboratory consultancy to audit Edison test results.
• Day 16 to 45: Demand access to raw data comparisons between Edison results and traditional lab results. Establish a direct whistleblower channel to the board.
• Day 46 to 90: Based on audit findings, either announce a pivot to traditional testing methods or implement a governance overhaul that removes super-voting rights.

2. Key Constraints

• Founder Control: Holmes can dismiss the entire board at her discretion due to the voting structure. Any oversight attempt must be framed as a requirement for future capital or regulatory survival.
• Information Asymmetry: The board does not know what it does not know. The CEO and COO control the flow of all technical and financial data.

3. Risk-Adjusted Implementation Strategy

The primary risk is a total loss of investor capital and criminal liability for directors. The implementation plan assumes the technology is flawed. Therefore, the strategy focuses on containment and legal protection for the board. The plan prioritizes regulatory compliance over market valuation. If the audit confirms technical failure, the board must transition the company to a traditional diagnostics provider or liquidate to return remaining capital to investors.

Executive Review and BLUF

1. BLUF

The Theranos board failed because it functioned as a social network rather than a governing body. By allowing a dual-class share structure and lacking technical expertise, the board ceded its fiduciary power to a founder who prioritized secrecy over science. The board must now choose between immediate confrontation or inevitable legal and criminal fallout. The recommendation is to force an independent audit immediately. This will likely destroy the 9 billion dollar valuation but is the only path to fulfill legal duties and protect public health. Speed is the only remaining tool to mitigate personal liability for the directors.

2. Dangerous Assumption

The most consequential unchallenged premise is that the reputation of the founder and the board members served as a proxy for the validity of the technology. The board assumed that because high-profile individuals were involved, the underlying science must be sound.

3. Unaddressed Risks

• Criminal Liability: Directors face personal legal exposure for patient harm if they continue to permit the use of inaccurate medical tests.
• Regulatory Shutdown: CMS or the FDA could shutter operations without warning, leaving the board with no time to manage an orderly transition or liquidation.

4. Unconsidered Alternative

The team did not consider an immediate merger with an established healthcare giant. An acquisition by a firm with deep medical expertise would have forced a due diligence process that either fixed the technology or exposed the issues earlier, potentially saving hundreds of millions in capital.

5. MECE Governance Assessment

• Structural Failure: Dual-class shares prevented effective oversight.
• Competency Failure: Lack of medical and scientific expertise on the board.
• Information Failure: Siloed internal culture and lack of audited financials.

Verdict: APPROVED FOR LEADERSHIP REVIEW